A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of MK0634 in Postmenopausal Women With Overactive Bladder

Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.

Clinical development of MK-0634 was discontinued. Study MK-0634-027 was a safety follow-up study to determine if there were any ocular effects of MK-0634 in participants from the United Kingdom who were exposed to MK-0634 during the 007 study.

Inclusion Criteria:

• Postmenopausal females (ages 40-74) with predominantly urge urinary incontinence overactive bladder episodes.
• Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards.

Exclusion Criteria:

• Patients must not suffer from diabetes insipidus
• Hyperglycemia
• Hypercalcemia
• Orthostatic hypotension
• Active/recurrent urinary tract infections (>6 episodes per year)
• Patients must be willing to discontinue their current OAB medication therapy.